The Radiation Syndrome Treatment Market will register a CAGR of more than 6% by 2023

Wednesday, December 5, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 4, 2018 /PRNewswire/ -- 109 pages, November 2018About this marketThe

advent of regenerative therapy is expected to help the market grow. The global radiation syndrome treatment market has seen strong advances in terms of treatment options. The advent of regenerative medicines such as stem-cell therapy is one among such
advances. In stem-cell therapy, the stem cells are taken from the patient and are re-inserted to replace the damaged cells to treat or prevent a disease. Technavio's analysts have predicted that the radiation syndrome treatment market will register a CAGR of more than 6% by 2023.Read the full report: https://www.reportlinker.com/p05638943 Market OverviewIncrease in nuclear testingThe increasing nuclear testing in South-East Asia in recent years has resulted in the rise in the symptoms of radiation toxicity and exposure in nearby countries. also, various scientists and pharmaceutical companies believe that the increasing testing of nuclear launches cause significant damage to the environment.Difficult to diagnoseA major share of the global radiation syndrome treatment market is dominated by acute radiation syndrome, which is highly progressive by nature. Acute radiation effects the patients in less than 24 hours of exposure to radiation. The lack of diagnostic devices for radiation syndrome is major challenge faced by the market.For the detailed list of factors that will drive and challenge the growth of the radiation syndrome treatment market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including Amgen and Neumedicines the competitive environment is quite intense. Factors such as the increase in nuclear testing and the advent of regenerative therapy, will provide considerable growth opportunities to radiation syndrome treatment manufactures. Amgen, Neumedicines, Partner Therapeutics, Tonix Pharmaceuticals, and Onconova Therapeutics are some of the major companies covered in this report.'With the presence of a considerable number of companies, this market appears to be fragmented. The market is expected to witness the emergence of many international and regional radiation syndrome therapeutic companies who offer therapeutics for the treatment of HSC syndrome, CNS syndrome, GI syndrome, and cardiovascular syndrome caused by radiation poisoning.'Read the full report: https://www.reportlinker.com/p05638943 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-radiation-syndrome-treatment-market-will-register-a-cagr-of-more-than-6-by-2023-300760051.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store